News


All series


All News

TNFSF11, also known as RANKL, shows potential as a genetic pathway in the prevention of breast cancer for women carrying BRCA1 mutations. Early study findings, published in Nature Medicine, show that a drug currently used in the treatment of osteoporosis, denosumab (Xgeva)-an inhibitor of RANKL-could also be used for the prevention and delay of tumor growth for BRCA1-mutation carriers.

While the ALSYMPCA trial led to the FDA approval of radium-223 dichloride (Xofigo), the phase III study left several questions to be answered regarding its use in metastatic castration-resistant prostate cancer (mCRPC), says Luke Nordquist, MD.

Researchers are hoping the results of a latestage efficacy and safety study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival, according to global principal investigator, Howard M. Sandler, MD.

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib (Jakafi) confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis. The JAK-2 inhibitor resulted in durable reductions in splenomegaly and improved overall survival, with patients experiencing no new or unexpected adverse events as a result of the long-term treatment.

The anti-CD38 monoclonal antibody isatuximab (SAR650984) showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma, according to updated findings from a phase II study presented at the 2016 ASCO Annual Meeting.

Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.

Despite the RESONATE-2 trial having demonstrated the efficacy of ibrutinib (Imbruvica) in treatment-naive elderly patients with chronic lymphocytic leukemia (CLL), Jennifer Brown, MD, explains that oncologists should carefully select patients to receive the drug depending on their age, comorbidities, and risk.

The investigational cancer vaccine CRS-207 may improve response and survival when given with chemotherapy in patients with malignant pleural mesothelioma (MPM) according to results of a phase Ib trial.